Researcher

Jingyi Li

Second Affiliated Hospital of Xi'an Jiaotong University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 11, 2026 · JOURNAL ARTICLE

A six-metabolite signature characterizes metabolically unhealthy obesity and reveals hidden metabolic risk within metabolically healthy obesity

Frontiers in Endocrinology

A metabolomic signature study with sound observational design, clear discriminatory performance (AUC 0.78), and mechanistic pathway findings, but based on cross-sectional association in a single population requiring validation before clinical use.

PromisingYanjun Liu Jingyi Li Binfeng Tang

Reported

Sample size13215

Proteomic subsampleapproximately 1408

Combined clinical-metabolomic mod…0.78

SEP 8, 2026 · JOURNAL ARTICLE

Time to benefit of perioperative immunotherapy among patients with resectable non-small-cell lung cancer

BMC Cancer

Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.

Strong EvidenceXiaohui Jia Wenming Bian Jingyi Li

Reported

Sample size5123

TTB for 1% EFS risk reduction1.02 months

TTB for 10% EFS risk reduction9.01 months